Editas Medicine
Gilmore is President and Chief Executive Officer of Editas Medicine and a member of the Editas Board of Directors. He joined Editas Medicine in June 2022.
Gilmore brings to Editas more than 20 years of experience in genetic medicine, neurobiology, and clinical development. Gilmore also has a track record of driving and leading several of biotech's most successful clinical programs and achieving marketing approvals for several medicines, including Amondys®, Vyondys0, Spinraza®, Plegridy@, and Tectidera@.
Editas Medicine
5 followers
Editas Medicine is a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Their goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.